Johnson & Johnson (JNJ)

Johnson & Johnson shares sit just under their 52-week high of $283.25, having risen 44.64% over the past year. The stock is trading 5.18% above its 50-day average and 12.49% above its 200-day average, and it is pulling back only slightly after a session-by-session climb through the autumn. The main question for holders is whether a stock that has run this far can keep rising while its valuation stays well above the healthcare sector. Analysts are broadly supportive, but the earnings record shows that a beat on the headline number has not reliably lifted the shares.

Johnson & Johnson beat the EPS estimate in seven of its last eight reports, but the share price fell in the first session after five of those beats. The October 13, 2026 report was the clearest case: EPS of $2.59 came in 2.78% above the $2.52 estimate, yet the shares dropped 5.73% in the first session. The pattern suggests investors are judging the company on guidance and on the size of the expectations already priced in, not on the headline quarter alone.

At a trailing P/E of 41.66, the stock trades 30.6% above the sector median of 31.9, and its price-to-sales ratio of 6.84 is 101.2% above the sector median of 3.4. Trailing GAAP EPS is $6.73, which is well below the adjusted quarterly run-rate used by analysts, so the trailing multiple looks high on either basis. The premium is supported by returns: the net profit margin is 16.20%, the operating margin is 25.74%, and return on equity is 20.02% against a sector median of 7.3%. Debt-to-equity of 0.55 keeps the balance sheet conservative. The business is therefore high-quality, but investors are paying for that quality in advance.

Of 23 analysts with a current rating, 16 rate the stock buy or strong buy, 6 hold it, and 1 sells it. Three months earlier the split was the same 16 buy ratings out of 23. Recent actions in October 2026 from Wells Fargo, Morgan Stanley, Leerink Partners, RBC Capital and Guggenheim all kept existing ratings rather than changing them. Insiders sold $193.5M of stock over the last 18 months across 20 sales and made one open-market purchase worth $258K. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market purchases.

The annual dividend of $5.28 gives a trailing yield of 1.88%. The stock's beta of 0.20 against the S&P 500 and a typical daily move of 1.86% point to a holding that has historically moved less than the broader market.

The base case is that the stock keeps its upward trend while earnings keep growing at a modest pace. Analysts expect revenue to rise 7.5% this fiscal year and EPS to rise 3.1% to $11.12, with a further 4.5% EPS gain to $11.62 next year. The median 12-month analyst target is $280.50, almost exactly the current price, and the highest target is $320.00. For the shares to move meaningfully higher from here, earnings growth would need to accelerate beyond the analysts' estimates. A fall toward the 50-day average of $266.55 would become more likely if the next reports fail to impress, since the stock has fallen on the first session after each of the last two reports despite beating estimates.

Support sits first at the 20-day EMA of $271.20, which the price has stayed above during the recent climb. The second support is the 50-day SMA at $266.55, and the third is the 200-day SMA at $249.21. Further down, the 52-week low is $193.07. Resistance sits at the 52-week high of $283.25, which the price is testing now. A daily close above that level would mark a new high for the stock, while a break back below the 20-day EMA would be the first sign that short-term momentum is fading.